Jean‐Damien Charrier

机构：Vertex Pharmaceuticals (United Kingdom)

发表论文 44 篇 · 总被引 1535 次 · h-index 13

代表论文

• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR (2011 · Nature Chemical Biology · 被引 651)
• Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents (2011 · Journal of Medicinal Chemistry · 被引 264)
• Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 (2014 · Oncotarget · 被引 202)
• The discovery of the potent aurora inhibitor MK-0457 (VX-680) (2009 · Bioorganic & Medicinal Chemistry Letters · 被引 101)
• Discovery and Structure−Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk) Inhibitors (2011 · Journal of Medicinal Chemistry · 被引 63)
• Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor (2019 · Journal of Medicinal Chemistry · 被引 56)